Tecan Revises 2024 Outlook Amid Market Challenges
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
- Latest
- Trending
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
A whale investor earns $153M on Ethereum after a 9-year hold, signaling potential market shifts.
The DOT's V2X initiative seeks to enhance road safety by enabling vehicle communication and reducing traffic fatalities.
Allstate offloads business unit for $2B to boost growth, stock climbs.
Explore how AI can support retirement planning and the limitations it currently faces in personalized financial advice.
David Salvagnini leads NASA's AI advancements, ensuring ethical and cutting-edge technology for space and Earth missions.
Solid-state batteries offer higher energy density and safety, advancing electric vehicle performance.
The U.S. dominates global AI growth with record investments, numerous start-ups, and job opportunities, according to a new report.
Lenovo's new AI-powered Chromebook Duet promises long battery life and advanced multimedia capabilities, thanks to Kompanio 838.
Citadel hires top talent beyond finance, favoring life winners. CEO Griffin likens employees to Olympic champions.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.